stockportfolio.pro
Stocks / CNMD vs COLL
CNMD vs COLL
CONMED Corporation and Collegium Pharmaceutical, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| CONMED Corporation (CNMD) | Collegium Pharmaceutical, Inc. (COLL) | |
|---|---|---|
| Market cap | $1.1B | $1.1B |
| Revenue (latest FY) | $1.37B | $780.57M |
| Net income (latest FY) | $47.05M | $62.87M |
| Revenue growth (5y CAGR) | 9.8% | 20.3% |
| Net margin | 3.4% | 8.1% |
| Return on equity | 4.6% | 20.8% |
| P/E ratio | 20.4 | 16.8 |
| Dividend yield | 2.2% | — |
| Profitable years (of last 10) | 9 | 5 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CNMD — free Open COLL — freeFrequently asked questions
Which is bigger, CNMD or COLL?
Collegium Pharmaceutical, Inc. is larger by market capitalization — $1.1B versus $1.1B.
Which grows faster, CNMD or COLL?
Over the last five fiscal years, Collegium Pharmaceutical, Inc. grew revenue faster — 20.3%/yr versus 9.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.